Latrice Shell
Gerontology · Augusta, GANPI 1528783065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,004 and has fallen 89.5% since, to $211 in 2025.
Across 223 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$825
- Lilly USA, LLC$417
- Pfizer$265
- GSK$260
- AbbVie$209
- Johnson & Johnson$191
- plus $2K from 21 others
What the payments were for
- Food & beverage$3,989100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $825 |
| Lilly USA, LLC | 29 | $417 |
| Pfizer | 15 | $265 |
| GSK | 17 | $260 |
| AbbVie | 20 | $209 |
| Johnson & Johnson | 8 | $191 |
| Novo Nordisk | 10 | $187 |
| Boehringer Ingelheim | 10 | $177 |
| Otsuka America Pharmaceutical, Inc. | 10 | $169 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $152 |
| Novartis | 8 | $129 |
| Bayer | 5 | $124 |
| Xeris Pharmaceuticals, Inc. | 6 | $120 |
| Exact Sciences | 7 | $108 |
| Phathom Pharmaceuticals, Inc. | 2 | $104 |
| Amgen | 6 | $100 |
| Esperion Therapeutics, Inc. | 6 | $92 |
| Azurity Pharmaceuticals, Inc. | 5 | $78 |
| Cequr Corporation | 2 | $66 |
| Astellas Pharma US Inc | 3 | $48 |
| Corcept Therapeutics | 2 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Mylan Specialty L.p. | 1 | $21 |
| Embecta Corp. | 1 | $18 |
| Merck | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
How this compares
$3,989 in reported general payments places this provider in the 85th percentile of 197 gerontology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $77,475 |
| JanuviaSitagliptin Phosphate | 98 | $75,006 |
| FarxigaDapagliflozin Propanediol | 62 | $62,407 |
| JardianceEmpagliflozin | 53 | $55,975 |
| EliquisApixaban | 55 | $44,711 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $44,356 |
| VraylarCariprazine Hcl | 29 | $42,920 |
| KerendiaFinerenone | 40 | $31,636 |
| MyrbetriqMirabegron | 32 | $28,123 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $25,129 |
| MounjaroTirzepatide | 23 | $24,144 |
| RybelsusSemaglutide | 16 | $23,761 |
| XareltoRivaroxaban | 22 | $17,664 |
| LinzessLinaclotide | 16 | $17,347 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $17,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $187 | $101,23689 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $825 | $93,202117 claims |
| MerckJanuvia, Belsomra | $15 | $80,564109 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $177 | $73,50377 claims |
| AbbVieVraylar, Linzess | $209 | $60,26745 claims |
| PfizerEliquis | $265 | $44,71155 claims |
| GSKTrelegy Ellipta | $260 | $44,35649 claims |
| BayerKerendia | $124 | $31,63640 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $28,12332 claims |
| Lilly USA, LLCMounjaro | $417 | $24,14423 claims |
| Johnson & JohnsonXarelto | $191 | $17,66422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 197 gerontology providers in Georgia.
Other gerontology in Augusta
- Joye RichardsonAugusta$2K
- Shikara JordanAugusta$1K
- Carolyn ClevengerAtlanta$65K
- Mitzi LewisAtlanta$37K
- Constance MeinkenAtlanta$36K
- Britni JohnsonSavannah$24K
- Doreen AbrigoWarner Robins$14K
- Taylor SwineaWaycross$10K
- Michelle DudleyMacon$10K
- Kathleen BradfordAtlanta$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.